AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 201 min read$BBIO

Kumar Neil sold $2.9M of BBIO

Kumar Neil (Chief Executive Officer) sold 34,980 shares of BridgeBio Pharma, Inc. (BBIO) at an average of $82.53 ($81.15–$83.77, $2.89M total) across 4 trades on 2026-08-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kumar Neil
Published Aug 20, 2026, 8:31 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 8:52 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$BBIO
Bearish
medium confidence
Mentioned
$BBIO
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BBIOBearishLow
01

Why it matters

The transaction reduces insider ownership and may be interpreted as a negative signal, though it could simply be a planned liquidity event.

02

Market read

Insider sales are closely monitored; this filing provides fresh data for traders evaluating BBIO.

03

What to watch

Potential upcoming clinical data releases or financing needs not disclosed.

Relevance 5/10Novelty 7/10Timing: post‑market 2026‑08‑20

Background

Form 4 filing reveals a CEO's open‑market sale under a pre‑arranged 10b5‑1 plan.

Company-level read

Ticker impact

$BBIOBearishMedium confidence
Context

CEO Kumar Neil sold 34,980 shares for $2.9M via a 10b5-1 plan, reducing his stake to 243,327 shares.

Expected impact

Possible modest downside pressure over the next few days.

Evidence & confidence

Insider sales by a CEO are watched closely; the $2.9M amount is material for a mid‑cap biotech, but not large enough to trigger a sharp move.

Market effects

Sector

May raise concerns for biotech sector investors tracking insider activity.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Minimal global impact.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company outlook.

Key entities

  • company
    BridgeBio Pharma, Inc.

    Biotech firm listed on Nasdaq (BBIO).

  • person
    Kumar Neil

    Chief Executive Officer of BridgeBio Pharma.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BBIO insider trading history →

Related articles

AUG 19
$BBIOMedAI 8/10

BridgeBio (BBIO) Q2 2026 Earnings Call Transcript

BridgeBio (BBIO) reported Q2 2026 revenue of $243.7M, up from $110.6M last year, driven by Attruby sales. Net loss was $152.2M, down from $181.9M. The company has $1.7B in cash, with three potential product launches planned. FDA accepted NDAs for BBP-418 and Encaleret, with target action dates in late 2026 and 2027, respectively. Management expects improving operating performance and potential profitability in 2027.

fool.com3 min
AUG 10
$BBIOMedAI 8/10

[BBIO Q2 2026 Earnings Call] Attruby Sales Hit $222M, Surge 120%, as BridgeBio Maps ‘Launch 2.0’ with $1.7B War Chest — BigGo Finance

BridgeBio Pharma (BBIO) reported Q2 2026 Attruby net product revenue of $222.4M, up from $71.5M a year earlier, and total revenue up 120% to $243.7M. Management said it has $1.7B cash after a $1B preferred equity deal. The company discussed CARDIO-TTRansform failure, regulatory progress on three NDAs, and expects breakeven toward 2027.

finance.biggo.com7 min
AUG 10
$BBIOMedAI 8/10

BridgeBio Pharma, Inc. (BBIO): Results of Operations and Financial Condition

BridgeBio Pharma, Inc. (BBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 bbio-20260630xex991.htm EX-99.1 Document Exhibit 99.1 BridgeBio Reports Second Quarter 2026 Financial Results and Corporate Updates - $243.7 million in total second quarter revenues, primarily comprised of $222.4 million of U.S. Attruby® net product revenue, with growth

SEC EDGAR 8-K7 min
JUL 23
$BBIOMedAI 8/10

FDA Accepts BridgeBio's Filing for Rare Genetic Disease Drug

BridgeBio Pharma (BBIO) said the FDA accepted its filing for encaleret, an oral investigational drug for autosomal dominant hypocalcemia type 1 (ADH1). A decision is expected by May 8, 2027. The company cited phase III CALIBRATE results and noted the FDA is not planning an advisory committee meeting. BBIO shares are up 8% YTD.

tradingview.com4 min